Adaptimmune Launches Tecelra Amid Strong Q2 Results
Adaptimmune's Tecelra launch marks progress in cell therapy, with strong Q2 financials and strategic plans for cancer treatment.
- Latest
- Trending
Adaptimmune's Tecelra launch marks progress in cell therapy, with strong Q2 financials and strategic plans for cancer treatment.
OPEC lowers oil demand growth estimate for 2024, highlighting challenges with Chinese market and production plans.
New VC firm to boost digital health startups with $21M fund, focusing on payer and pharma engagement for better patient ...
Stock markets await CPI, PPI, and retail sales data; gold surpasses $2,500, reflecting market uncertainty.
New rule to enhance cybersecurity for defense contractors. Comments open until October 2024.
Sinovac's 2024 revenue drops amidst market challenges, with ongoing vaccine development and international market expansions.
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
Appian partners with OSTech to improve business efficiency by 25% using automation and digital transformation services.
WeRide can now test robotaxis with passengers in California, but can't charge fares. The move precedes a potential $5B IPO.
The IEA reports a continued decline in Chinese oil demand amid weakened industrial activity and a struggling economy.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.